<h4>Background</h4>Adjuvant endocrine therapy is a cornerstone in managing estrogen receptor-positive early breast cancer but may adversely affect metabolic health, including weight gain, insulin resistance, and dyslipidemia. The gene discussed is ESR1; the disease is breast carcinoma.